Monitoring Emerging Human Immunodeficiency Virus Drug Resistance in Sub-Saharan Africa in the Era of Dolutegravir.
HIVDR
dolutegravir
surveillance
Journal
The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675
Informations de publication
Date de publication:
01 02 2022
01 02 2022
Historique:
received:
16
06
2021
accepted:
19
07
2021
pubmed:
21
7
2021
medline:
10
5
2022
entrez:
20
7
2021
Statut:
ppublish
Résumé
Dolutegravir-based regimens are now standard of care for human immunodeficiency virus treatment for millions of people around sub-Saharan Africa. To ensure its continued efficacy, monitoring of emerging drug resistance that inform a treatment strategy among those failing is crucial. In this report, we outline the US President's Emergency Plan for AIDS Relief to leverage viral load infrastructure to implement effective drug resistance surveillance in the countries it supports.
Identifiants
pubmed: 34282844
pii: 6324299
doi: 10.1093/infdis/jiab382
doi:
Substances chimiques
Anti-HIV Agents
0
Heterocyclic Compounds, 3-Ring
0
Oxazines
0
Piperazines
0
Pyridones
0
dolutegravir
DKO1W9H7M1
Types de publication
Journal Article
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
364-366Informations de copyright
Published by Oxford University Press for the Infectious Diseases Society of America 2021.